Literature DB >> 6363033

[Spirochete etiology of erythema chronicum migrans disease].

R Ackermann, J Kabatzki, H P Boisten, A C Steere, R L Grodzicki, S Hartung, U Runne.   

Abstract

From ticks of the type Ixodes ricinus, 19 strains of a spirochete were isolated at three places of infection of erythema chronicum migrans disease. The spirochete was immunologically related to Borrelia duttoni, Treponema pallidum and Ixodes dammini spirochete, the causative organism of North American erythema chronicum migrans disease (Lyme disease). The isolated spirochete differed from the North American one in its reaction with monoclonal antibodies and possibly in its electronmicroscopic structure. A corresponding spirochete was isolated from the blood of a woman with erythema chronicum migrans. Of 39 patients with erythema chronicum migrans mostly treated with antibiotics 50% had increased IgG antibody titre (1:64 to 1:1024) against the isolated spirochete, while among 51 untreated patients with tick-transmitted meningopolyneuritis 90% had increased IgG antibody titres. Fourfold antibody titres increases or falls were found on 50 occasions. IgG antibody titres up to 1:64 were demonstrated also in CSF, in 22 instances with significant changes. Increased serum IgM antibody titres of 1:32 to 1:256 were observed in 20% and 68%, respectively, of patients. These findings suggest that the isolated spirochete is the causative agent of erythema chronicum migrans disease in Europe. Its antigen structure and arrangement is similar to that of the causative agent of Lyme disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6363033     DOI: 10.1055/s-2008-1069145

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  20 in total

1.  Chronic borrelia encephalomyeloradiculitis with severe mental disturbance: immunosuppressive versus antibiotic therapy.

Authors:  H H Kollikowski; G Schwendemann; M Schulz; H Wilhelm; H J Lehmann
Journal:  J Neurol       Date:  1988-01       Impact factor: 4.849

2.  Serodiagnosis of erythema migrans and acrodermatitis chronica atrophicans by the Borrelia burgdorferi flagellum enzyme-linked immunosorbent assay.

Authors:  K Hansen; E Asbrink
Journal:  J Clin Microbiol       Date:  1989-03       Impact factor: 5.948

3.  Lyme arthritis: clinical features, serological, and radiographic findings of cases in Germany.

Authors:  P Herzer; B Wilske; V Preac-Mursic; G Schierz; M Schattenkirchner; N Zöllner
Journal:  Klin Wochenschr       Date:  1986-03-03

4.  Diagnostic significance of IgG-synthesizing activated B cells in acute inflammatory diseases of the central nervous system.

Authors:  H J Schädlich; K Felgenhauer
Journal:  Klin Wochenschr       Date:  1985-06-03

5.  Measurement of antibodies to the Borrelia burgdorferi flagellum improves serodiagnosis in Lyme disease.

Authors:  K Hansen; P Hindersson; N S Pedersen
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

6.  Lymphocytic meningoradiculitis of Bannwarth and erythema migrans disease.

Authors:  K Weber
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

7.  Serological diagnosis of erythema migrans disease and related disorders.

Authors:  B Wilske; G Schierz; V Preac-Mursic; K Weber; H W Pfister; K Einhäupl
Journal:  Infection       Date:  1984 Sep-Oct       Impact factor: 3.553

8.  Comparison of Western blot and enzyme-linked immunosorbent assay for diagnosis of Lyme borreliosis.

Authors:  M Karlsson; I Möllegård; G Stiernstedt; B Wretlind
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

9.  Relapsing fever and its serological discrimination from Lyme borreliosis.

Authors:  P M Rath; G Rögler; A Schönberg; H D Pohle; F J Fehrenbach
Journal:  Infection       Date:  1992 Sep-Oct       Impact factor: 3.553

10.  Meningitis due to Borrelia burgdorferi in the initial stage of Lyme disease.

Authors:  H I Huppertz; V Sticht-Groh
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.